
It has no real impact at the moment, but going forward it could help the company’s efforts to develop belinostat for the European market, says Topotarget CEO Anders Vadsholdt following the announcement that the company’s most promising candidate drug had achieved Orphan Drug-status in the EU.
“For everyone, also potential partners, it is of great value that we’ve been given these opportunities. Because it is not just within PTCL (Peripheral T Cell Lymphoma) that we can gain this status, we can probably gain it for other indications as well. I believe, it will make it easier to attract investors and partners, as it is a validation,” Anders Vadsholdt tells Medwatch.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app